Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Research & Development Pharma, effective September 1, 2026. Fontoura brings over 25 years of experience in medicine and pharmaceutical innovation, having held senior roles at Roche and Xaira Therapeutics. He will lead Sanofi's R&D efforts to advance its pipeline and accelerate delivery of new medicines. This leadership change comes as Sanofi continues to transform its R&D and strengthen its position in immunology and other therapeutic areas.
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
Japan's Ministry of Health has approved Sanofi's Sarclisa subcutaneous (SC) formulation for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval is based on the IRAKLIA phase 3 study showing the SC form is...
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
COUR Pharma secured $50 million in a Series B funding round led by Lumira Ventures and Roche Venture Fund, with new investment from Sanofi. The funds will support clinical trials of CNP-103, a novel immune tolerance therapy targeting type 1 diabetes ...
